ENTA - Enanta Pharma presents new EDP-721 data in HBV at EASL congress

Enanta Pharmaceuticals (ENTA) announces new preclinical data for EDP-721, an oral hepatitis B virus ((HBV)) RNA destabilizer being developed for use in an all-oral combination regimen for HBV.The data demonstrate potent, selective and pangenotypic inhibition of HBV surface antigen (HBsAg), with up to a 3-log drop in the AAV-HBV mouse model.EDP-721 was also shown to exhibit synergistic antiviral activity in vitro when combined with nucleos(t)ide reverse transcriptase inhibitors or the HBV core inhibitor EDP-514.Enanta expects to initiate a Phase 1 single and multiple dose ascending study to evaluate the safety and tolerability of EDP-721 in healthy volunteers in mid-2021.The research was presented during the EASL International Liver Congress 2021.Earlier, the company reported positive data from Phase 1b study of EDP-514 in viremic chronic HBV patients.

For further details see:

Enanta Pharma presents new EDP-721 data in HBV at EASL congress